NLS Pharmaceutics Ltd.
We are an innovative biopharmaceutical company engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders, including narcolepsy and ADHD (Attention Deficit Hyperactivity Disorder). CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders.
(Note: This is a unit offering.)
|Address||Alter Postplatz 2, CH-6370 Stans, Switzerland|
|View Prospectus:||NLS Pharmaceutics Ltd.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-6.5 mil (last 12 months)|
|Price range||$5.00 - $6.00|
|Est. $ Volume||$20.0 mil|
|Manager / Joint Managers||Maxim Group LLC|
|CO-Managers||Brookline Capital (A division of Arcadia Securities)|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|